Register Now for NAAF's 39th Annual Patient Conference June 27-30, 2024 in Washington, D.C.!
Note: Although this study is fully enrolled, additional pediatric studies are expected soon.
The purpose of this study is to collect data to support the appropriate dose of the study medicine for future studies in children 6 to 11 years of age with severe alopecia areata. There will be about 12 to 15 participants taking part in this study.
Your child may qualify to participate in this study if they: *
*Other eligibility criteria also apply.
Participants will have three office visits, one at screening, one at the beginning of treatment, and one at the end of treatment or early end of the study. Participants will be asked to take one capsule of the study medicine (dissolved in water) each day, in the morning, for one week.
Participants will be in this study for approximately two months, including a 28-day screening period, 7- day treatment period, and a 35-42 day follow-up period. Participants will be contacted by phone by their trial doctor or the trial nurse at least four times between their first and last dose of trial medicine.
Participants are free to stop being in this study at any time and for any reason. Your participation in this study is at no cost to you.
This study is taking place at research sites throughout the United States. For more information on the study, visit: www.PfizerPedsAlopeciaAreatastudy.com or contact a study site listed below.
CALIFORNIA California Dermatology & Clinical Research Institute 561 Saxony Place Suite 102 Encinitas CA 92024 Contact: Oralia Cruz Phone: 760-203-3839
FLORIDA Pediatric Skin Research LLC 4425 Ponce de Leon Blvd Suite 115 Coral Gables, FL 33146 Contact: Evelyn Hernandez Phone: 786-585-5774
